Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system

Experimental Neurology

Volumn 263, Issue , 2015, Pages 221-234

  Hoefer, Melanie M ^a   Sanchez, Ana B ^a   Maung, Ricky ^a   de Rozieres, Cyrus M ^a   Catalan, Irene C ^a   Dowling, Cari C ^a   Thaney, Victoria E ^a   Piña Crespo, Juan ^a   Zhang, Dongxian ^a   Roberts, Amanda J ^b   Kaul, Marcus ^a,c  

^a BURNHAM INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavior; Electrophysiology; Gene expression; HIV 1 gp120; Methamphetamine; NeuroAIDS; Neuropathology; Transgenic animal model

Indexed keywords

GLYCOPROTEIN GP 120; METHAMPHETAMINE; CENTRAL STIMULANT AGENT; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN CORTEX; CELL LOSS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DENDRITE; DOWN REGULATION; DRUG WITHDRAWAL; FEMALE; GABAERGIC TRANSMISSION; GENE EXPRESSION; GLUTAMATERGIC NEUROTRANSMISSION; HIPPOCAMPUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INJURY; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SEX DIFFERENCE; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPTOSOME; UPREGULATION; ADDICTION; ANIMAL; ANIMAL BEHAVIOR; BRAIN; COMPLICATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; PATCH CLAMP TECHNIQUE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNOHISTOCHEMISTRY; METHAMPHETAMINE; MICE; MICE, TRANSGENIC; PATCH-CLAMP TECHNIQUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANCE-RELATED DISORDERS; TRANSCRIPTOME;

EID: 84910625727     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.09.010     Document Type: Article

References (102)

1. Abel M.S., Kohli N. GABA-transaminase antisense oligodeoxynucleotide modulates cocaine- and pentylenetetrazol-induced seizures in mice. Metab. Brain Dis. 1999, 14:253-263.
2. Albertson T.E., et al. Methamphetamine and the expanding complications of amphetamines. West. J. Med. 1999, 170:214-219.
3. Antinori A., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
4. Bach M.E., et al. Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. Cell 1995, 81:905-915.
5. Bao J.X., et al. Involvement of pre- and postsynaptic mechanisms in posttetanic potentiation at Aplysia synapses. Science 1997, 275:969-973.
6. Barde Y.A., et al. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982, 1:549-553.
7. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93:74-104.
8. Bellocchio E.E., et al. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 2000, 289:957-960.
9. Berger J.R., et al. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1994, 8:67-71.
10. Besl B., Fromherz P. Transistor array with an organotypic brain slice: field potential records and synaptic currents. Eur. J. Neurosci. 2002, 15:999-1005.
11. Block M.R., et al. Purification of an N-ethylmaleimide-sensitive protein catalyzing vesicular transport. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:7852-7856.
12. Borkholder D.A., et al. Microelectrode arrays for stimulation of neural slice preparations. J. Neurosci. Methods 1997, 77:61-66.
13. Bourque M., et al. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 2011, 36:955-969.
14. Bramham C.R. Local protein synthesis, actin dynamics, and LTP consolidation. Curr. Opin. Neurobiol. 2008, 18:524-531.
15. Brew B.J., et al. Neurodegeneration and ageing in the HAART era. J. Neuroimmune Pharmacol. 2009, 4:163-174.
16. Buckle V.J., et al. Chromosomal localization of GABAA receptor subunit genes: relationship to human genetic disease. Neuron 1989, 3:647-654.
17. Cadet J.L., Krasnova I.N. Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation. Neurotox. Res. 2007, 12:181-204.
18. Cadet J.L., et al. Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One 2009, 4:e7812.
19. Cadet J.L., et al. Methamphetamine preconditioning causes differential changes in striatal transcriptional responses to large doses of the drug. Dose Response 2011, 9:165-181.
20. Carey C.L., et al. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav. 2006, 10:185-190.
21. Cass W.A. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J. Pharmacol. Exp. Ther. 1997, 280:105-113.
22. Cisneros I.E., Ghorpade A. HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS. Curr. HIV Res. 2012, 2012:392-406.
23. Coppola T., et al. Molecular cloning of a murine N-type calcium channel alpha 1 subunit. Evidence for isoforms, brain distribution, and chromosomal localization. FEBS Lett. 1994, 338:1-5.
24. Cuesta M., et al. The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2012, 45:145-155.
25. Ebralidze A.K., et al. Modification of NMDA receptor channels and synaptic transmission by targeted disruption of the NR2C gene. J. Neurosci. 1996, 16:5014-5025.
26. Eisch A.J., Marshall J.F. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 1998, 30:433-445.
27. Enna S.J., Gallagher J.P. Biochemical and electrophysiological characteristics of mammalian GABA receptors. Int. Rev. Neurobiol. 1983, 24:181-212.
28. Ferris M.J., et al. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci. Biobehav. Rev. 2008, 32:883-909.
29. Flora G., et al. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 2003, 179:60-70.
30. Glass J.D., et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 1995, 38:755-762.
31. Heaton R.K., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010, 75:2087-2096.
32. Henry B.L., et al. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav. Brain Res. 2013, 236:210-220.
33. Henry B.L., et al. Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav. Pharmacol. 2014, 25:12-22.
34. Heyes M.P., et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 1991, 29:202-209.
35. Holmes A., et al. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 2002, 1:55-69.
36. Hughes J.R. Post-tetanic potentiation. Physiol. Rev. 1958, 38:91-113.
37. Jayanthi S., et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:868-873.
38. Johansson B., et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9407-9412.
39. Johnson M.A., et al. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
40. Kang Y.J., et al. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann. Neurol. 2010, 68:342-352.
41. Kapadia F., et al. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin. Infect. Dis. 2005, 41:1027-1034.
42. Kauer J.A., et al. NMDA application potentiates synaptic transmission in the hippocampus. Nature 1988, 334:250-252.
43. Kaul M., et al. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001, 410:988-994.
44. Kaul M., et al. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005, 12(Suppl. 1):878-892.
45. Kesby J.P., et al. Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict. Biol. 2012, 10.1111/adb.12023.
46. Korte M., et al. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8856-8860.
47. Kraft-Terry S.D., et al. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 2009, 64:133-145.
48. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
49. Krucker T., et al. Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 1998, 83:691-700.
50. Kuczenski R., et al. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 2007, 207:42-51.
51. Ladenheim B., et al. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol. Pharmacol. 2000, 58:1247-1256.
52. Langford D., et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J. Acquir. Immune Defic. Syndr. 2003, 34:467-474.
53. Lee Y.W., et al. Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain. J. Neurosci. Res. 2002, 70:82-89.
54. Lisman J., et al. Mechanisms of CaMKII action in long-term potentiation. Nat. Rev. Neurosci. 2012, 13:169-182.
55. -δδCT method. Methods 2001, 25:402-408.
56. Maeda N., et al. Purification and characterization of P400 protein, a glycoprotein characteristic of Purkinje cell, from mouse cerebellum. J. Neurochem. 1988, 51:1724-1730.
57. Maragos W.F., et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J. Neurochem. 2002, 83:955-963.
58. Mark K.A., et al. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 2004, 24:11449-11456.
59. Martin S.J., et al. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 2000, 23:649-711.
60. Masliah E., et al. Selective neuronal vulnerability in HIV encephalitis. J. Neuropathol. Exp. Neurol. 1992, 51:585-593.
61. Masliah E., et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC group. The HIV Neurobehavioral Research Center. Ann. Neurol. 1997, 42:963-972.
62. Maung R., et al. Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury. J. Neuroimmune Pharmacol. 2012, 7:306-318.
63. Maung R., et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J. Immunol. 2014, 193:1895-1910.
64. 11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
65. Mehta A., et al. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 2013, 698:6-18.
66. Minichiello L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 2009, 10:850-860.
67. Mitchell S.J., et al. Methamphetamine use and sexual activity among HIV-infected patients in care-San Francisco, 2004. AIDS Patient Care STDS 2006, 20:502-510.
68. Nath A., et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J. Psychopharmacol. 2000, 14:222-227.
69. Okamoto S., et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. Cell Stem Cell 2007, 1:230-236.
70. Paylor R., et al. Learning impairments and motor dysfunctions in adult Lhx5-deficient mice displaying hippocampal disorganization. Physiol. Behav. 2001, 73:781-792.
71. Puckett C., et al. Molecular cloning and chromosomal localization of one of the human glutamate receptor genes. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:7557-7561.
72. Rippeth J.D., et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 2004, 10:1-14.
73. Roberts A.J., et al. Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J. Neurosci. Methods 2010, 186:222-225. 10.1016/j.jneumeth.2009.11.007.
74. Sato K., et al. The differential expression patterns of messenger RNAs encoding non-N-methyl-d-aspartate glutamate receptor subunits (GluR1-4) in the rat brain. Neuroscience 1993, 52:515-539.
75. Sato H., et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 1999, 274:11455-11458.
76. Schmued L.C., Bowyer J.F. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 1997, 759:135-140.
77. Scott J.C., et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev. 2007, 17:275-297.
78. Seil F.J., Drake-Baumann R. TrkB receptor ligands promote activity-dependent inhibitory synaptogenesis. J. Neurosci. 2000, 20:5367-5373.
79. Sekine Y., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2006, 63:90-100.
80. Silverstein P.S., et al. Methamphetamine toxicity and its implications during HIV-1 infection. J. Neurovirol. 2011, 10.1007/s13365-011-0043-4.
81. Silverstein P.S., et al. HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr. HIV Res. 2012, 10:369-383.
82. Sommer B., et al. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991, 67:11-19.
83. Sullivan K.A., et al. Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and amino acid sequences of the alpha chains. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6687-6691.
84. Sulzer D., et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 1995, 15:4102-4108.
85. Swant J., et al. Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus. PLoS One 2010, 5:e11382.
86. Szpirer C., et al. The genes encoding the glutamate receptor subunits KA1 and KA2 (GRIK4 and GRIK5) are located on separate chromosomes in human, mouse, and rat. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11849-11853.
87. Takai S., et al. Localization of the gene (SLC1A3) encoding human glutamate transporter (GluT-1) to 5p13 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 1995, 69:209-210.
88. Takamori S., et al. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000, 407:189-194.
89. Theodore S., et al. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr. HIV Res. 2007, 5:301-313.
90. Thompson P.M., et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 2004, 24:6028-6036.
91. Toggas S.M., et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994, 367:188-193.
92. Tsai L.H., et al. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423.
93. Urbina A., Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin. Infect. Dis. 2004, 38:890-894.
94. Usdin M.T., et al. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 1999, 8:839-846.
95. Volkow N.D., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 2001, 158:2015-2021.
96. Wesselingh S.L., et al. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J. Neuroimmunol. 1997, 74:1-8.
97. Wilcox A.S., et al. Human chromosomal localization of genes encoding the gamma 1 and gamma 2 subunits of the gamma-aminobutyric acid receptor indicates that members of this gene family are often clustered in the genome. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:5857-5861.
98. Wilson J.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
99. Wuchter J., et al. A comprehensive small interfering RNA screen identifies signaling pathways required for gephyrin clustering. J. Neurosci. 2012, 32:14821-14834.
100. Yamada K., et al. Changes in expression and distribution of the glutamate transporter EAAT4 in developing mouse Purkinje cells. Neurosci. Res. 1997, 27:191-198.
101. Yamamoto B.K., Bankson M.G. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 2005, 17:87-117.
102. Zink W.E., et al. Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J. Neurosci. 2002, 22:2096-2105.